This product does not require an MSDS and we do not have MSDS to offer.
Please use this email as confirmation. We have datasheets and technical
information available online through www.scbt.com. Please let me know
if you need further assistance.
SANTA CRUZ BIOTECHNOLOGY, INC.
The Power to Question
gp130 (C-20): sc-655
Santa Cruz Biotechnology, Inc.
1.800.457.3801 831.457.3800 fax 831.457.3801 Europe
+00800 4573 8000 49 6221 4503 0 www.scbt.com
gp130 (C-20) is recommended for detection of gp130 of mouse, rat and
human origin by Western Blotting (starting dilution 1:200, dilution range
1:100-1:1000), immunoprecipitation [1–2 µg per 100–500 µg of total protein
(1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution
Suitable for use as control antibody for gp130 siRNA (h): sc-29333 and
gp130 siRNA (m): sc-35502.
Molecular Weight of gp130: 130 kDa.
Positive Controls: human colon carcinoma, WEHI-231 whole cell lysate:
sc-2213 or HeLa whole cell lysate: sc-2200.
SELECT PRODUCT CITATIONS
1. Hirota, H., et al. 1999. Loss of a gp130 cardiac muscle cell survival path-
way is a critical event in the onset of heart failure during biomechanical
stress. Cell 97: 189-198.
2. Kasza, A., et al. 2001. Differential effects of oncostatin M and leukaemia
inhibitory factor expression in astrocytoma cells. Biochem. J. 355: 307-314.
3. Hurst, S.M., et al. 2002. Secretion of oncostatin M by infiltrating neu-
trophils: regulation of IL-6 and chemokine expression in human mesothelial
cells. J. Immunol. 169: 5244-5251.
4. Blanchard, F., et al. 2003. DNA methylation controls the responsiveness
of hepatoma cells to leukemia inhibitory factor. Hepatology 38: 1516-1528.
5. Niculescu, T., et al. 2004. Effects of complement C5 on apoptosis in
experimental autoimmune encephalomyelitis. J. Immunol. 172: 5702-5706.
For research use only, not for use in diagnostic proce